Coronary/Structural Heart

Supporting Cells in the Heart Contribute to Cardiac Disease

WASHINGTON, April 9, 2018 /PRNewswire/ — An article published in Experimental Biology and Medicine (Volume 243, Issue 7, April, 2018) reports that supporting cells in the heart, known as fibroblasts, are selectively activated by factors present in heart disease. The study, led by Dr. Megan McCain, Assistant Professor in the Department of Biomedical Engineering and Department […]

Recently Published CARRESS-HF Per Protocol Analysis Demonstrates Greater Fluid Reduction in Heart Failure Patients Using CHF Solutions’ Aquadex FlexFlow System

EDEN PRAIRIE, Minn., April 10, 2018 (GLOBE NEWSWIRE) — A recently published study in the European Journal of Heart Failure highlighted a per protocol analysis of the CARRESS-HF study, which demonstrated that ultrafiltration with the Aquadex Flex Flow System by CHF Solutions, Inc. (Nasdaq:CHFS) was associated with a higher cumulative fluid loss (p=0.003), […]

NobleStitch™ EL Italian Registry Data Published In EuroIntervention

ROME, April 9, 2018 /PRNewswire/ — Nobles Medical Technologies II, Inc. (NMT2) has announced the first peer-reviewed publication of data for PFO closure using the NobleStitch™ EL. The first systematic clinical experience by using the revolutionary “deviceless” technique to close Patent Foramen Ovale (PFO) has been recently published in the prestigious peer-reviewed European […]

Key Findings of the Global Prosthetic Heart Valves Market | Technavio

LONDON–(BUSINESS WIRE)–The latest market research report by Technavio on the global prosthetic heart valves market predicts a CAGR of above 12% during the period 2018-2022. The report segments the global prosthetic heart valves market by product (transcatheter heart valves, tissue heart valves, and mechanical heart valves), by end-user (hospitals and ASCs), and by geography (the Americas, EMEA, and […]

Phase III CardiAMP Heart Failure Trial Featured in American Heart Journal

SAN CARLOS, Calif., April 9, 2018 /PRNewswire/ — BioCardia®, Inc., [OTC: BCDA] a leader in cardiovascular regenerative medicine, today announced the publication of the Phase III CardiAMP Heart Failure Trial design paper in the American Heart Journal. Titled “The CardiAMP Heart Failure Trial: A Randomized Controlled Pivotal Trial of High Dose Autologous Bone […]

Medtronic Announces Renal Denervation Pivotal Trial for the Treatment of Hypertension

DUBLIN – April 9, 2018 – Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) approval to begin an investigational device exemption (IDE) pivotal trial to evaluate the Symplicity Spyral(TM) renal denervation system in patients with high blood pressure (hypertension). Renal denervation is a minimally invasive procedure intended […]

Canon Medical Systems’ Aquilion Precision Receives FDA Clearance

TUSTIN, Calif.–(BUSINESS WIRE)–Canon Medical Systems USA, Inc.’s newly FDA-cleared Aquilion Precision™ is the world’s first Ultra-High Resolution CT system (UHR CT). The system can resolve anatomy as small as 150 microns and is designed to provide more than twice the resolution, typically seen only in cath labs. Containing an all-new detector […]

Cardiva Medical® Announces FDA Approval of VASCADE® Vascular Closure System for Use in Femoral Vein Closure

SANTA CLARA, Calif.–(BUSINESS WIRE)–Cardiva Medical®, an innovator in the field of vascular closure, today announced the company has received approval from the U.S. Food and Drug Administration (FDA) for an expanded indication of the VASCADE® Vascular Closure System. Already approved for use in arterial closure, VASCADE is now FDA approved […]

CARMAT: Continuing Progress in Line with the Objective of Obtaining CE Marking in 2019

PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (Paris:ALCAR) (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart project, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, today announced an update on the progress of the PIVOTAL study and the latest developments regarding […]

Abiomed (ABMD) Reports European Approval (CE Marking) for Impella 5.5 & 1st Patient Treated at University Heart Center Hamburg

Abiomed, Inc. (NASDAQ: ABMD) announced today that the Impella 5.5™ heart pump received CE marking1 approval in Europe and the first patient was treated at University Heart Center in Hamburg, Germany. The Impella 5.5 heart pump further enhances Abiomed’s product portfolio and provides physicians a 30-day, ambulatory, wean-able, forward flow heart pump. […]